I am a
Home I AM A Search Login

Papers of the Week

Papers: 24 Feb 2024 - 1 Mar 2024

2024 Feb 27



Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience.


Chhabra N, Mead-Harvey C, Dodoo CA, Iser C, Taylor H, Chaudhary H, Vanood A, Dodick DW


Erenumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor and is approved for the preventative treatment of migraine in adults. CGRP is involved in the regulation of vasomotor tone under physiologic and pathologic conditions, including hypertension. While there has not been evidence of hypertension in preclinical models or clinical trials, post-marketing data suggest erenumab may be associated with hypertension. This led to a warning in the United States Food and Drug Administration prescribing information for erenumab.